市场调查报告书
商品编码
1541630
2024-2032 年按应用(糖尿病、肥胖、心血管疾病、中枢神经系统疾病、呼吸道疾病、戒烟等)、最终用途(患者、提供者、付款人、雇主等)和地区分類的数位治疗市场报告Digital Therapeutics Market Report by Application (Diabetes, Obesity, CVD, CNS Disease, Respiratory Diseases, Smoking Cessation, and Others), End Use (Patients, Providers, Payers, Employers, and Others), and Region 2024-2032 |
2023年全球IMARC Group治疗市场规模达60亿美元。对数位行为监测治疗的需求不断增长、慢性病盛行率不断上升以及大众对个人健康和健身意识的不断提高是推动市场的关键因素之一。
智慧型手机和平板电脑使用量的增加推动市场成长
对智慧型手机和平板电脑的日益依赖,加上不同的医疗保健应用程序,正在推动数位治疗市场的成长。智慧型手机和基于平板电脑的医疗保健应用程式具有降低用药错误率、促进预防性护理和更准确的人员配置等众多优势。个人科技设备在医疗保健领域的使用不断增加,刺激了对数位疗法 (DTx) 治疗的需求。 DTx 正在增强患者获得治疗的安全性和有效性,以不同语言呈现讯息,提供有关疾病和治疗的相关信息,并扩大医生护理患者的能力。此外,它是一种先进的护理服务模式,可以在家中轻鬆实施,并消除与传统疗法相关的任何耻辱。
报告涵盖了市场结构、主要参与者的市场份额、参与者定位、最佳制胜策略、竞争仪表板和公司评估象限等竞争分析。此外,也提供了所有主要公司的详细资料。市场结构适度分散,有大量全球和区域参与者。此外,由于研发(R&D)创新和併购(M&A)数量的增加,该市场的竞争环境正在加剧。由于市场结构分散、产品差异化和转换成本较低,数位治疗行业的新进入者数量适中。此外,行动医疗开发商数量的不断增加也加剧了新进入者的巨大威胁。然而,先进技术的专利要求和高成本以及严格的监管程序减少了新进入者的威胁。
什么是数位治疗?
数位疗法 (DTx) 是一种由高品质软体程式驱动的实证治疗介入措施,用于预防、管理或治疗医学病症或疾病。它是软体即医疗设备 (SaMD) 的一种形式,依靠软体介入来改变患者的行为并帮助治疗他们的病情。 DTx 是一类快速且新兴的疗法,利用软体独立治疗疾病或优化治疗。它有助于预防和管理多种疾病和病症,如2 型糖尿病、充血性心臟衰竭、肥胖、阿兹海默症、失智症、气喘、药物滥用、注意力不足过动症(ADHD)、高血压、焦虑、忧郁、和其他几个。 DTx 还有助于提高患者用药依从性,并支持医疗保健专业人员 (HCP) 以数位方式管理患者和业务。
COVID-19大流行的到来可谓医疗保健产业的分水岭。它极大地改变了医疗保健提供的方式,同时暴露了世界各国政府在充分应对全球医疗保健紧急情况方面缺乏准备。第一线卫生工作者参与管理 COVID-19 患者,但患有其他健康问题的患者,尤其是慢性健康问题的患者,由于推迟或避免去诊所就诊,因此遇到了困难。此外,由于患有合併症(尤其是肥胖、心臟併发症和糖尿病)的患者中的 COVID-19 结局比没有合併症的患者更差,因此要求这些患者额外保持警惕。这场大流行也带来了相当一部分精神健康障碍,包括忧郁、焦虑和戒断,由于缺乏面对面的就诊,这些疾病的管理是一个挑战。这些相互关联的事件促使医疗保健提供者寻求数位健康解决方案来应对健康危机。在 COVID-19 爆发期间,数位医疗技术的采用出现了积极的趋势,提高了医疗保健营运和服务提供的效率和有效性。疫情发生后,DTx应用在各领域的采用加速了数倍。此外,COVID-19 大流行透过改变患者参与度和整合整个医疗保健领域的资料,增加了虚拟和家庭护理技术的采用。
目前,2 型糖尿病患者对 DTx 的需求不断增加,以控制疾病并使他们能够使用支援物联网 (IoT) 的胰岛素帮浦和其他健康监测系统。再加上对数位行为监测治疗的需求不断增长,以确保药物依从性和健康生活方式的改变,这是支持市场成长的关键因素之一。此外,与传统治疗相比,越来越多地使用 DTx 来减少更多后续检查和復发的需要,这提供了良好的市场前景。此外,心臟病、中风、癌症、肥胖和关节炎等慢性疾病的盛行率也在增加。再加上大众对个人健康和健身意识的不断提高,正在推动市场的成长。此外,对 DTx 的需求不断增长,以帮助医生管理患者对医疗方案的依从性,并建立一个综合的健康生态系统,使资料能够在付款人、提供者和药房等不同利益相关者之间无缝传输,这正在推动市场的成长。
The global digital therapeutics market size reached US$ 6.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 26.8 Billion by 2032, exhibiting a growth rate (CAGR) of 17.5% during 2024-2032. The growing demand for digital behavior-monitoring treatment, increasing prevalence of chronic diseases, and rising awareness among the masses about personal health and fitness represent one of the key factors driving the market.
Increasing Usage of Smartphones and Tablets Propelling Market Growth
The rising reliance on smartphones and tablets, coupled with different healthcare apps, is propelling the growth of the digital therapeutics market. Smartphones and tablet-based healthcare apps have numerous advantages over the lower rate of medication errors, facilitating preventive care, and more accurate staffing. The increasing utilization of personal technological devices in healthcare is catalyzing the demand for digital therapeutics (DTx) treatments. DTx is enhancing patient access to the safety and effectiveness of treatments, presenting information in different languages, providing relevant information about diseases and treatments, and expanding the ability of physicians to care for patients. Furthermore, it is an advanced mode of care delivery, which can be easily implemented at home and eliminates any stigma associated with traditional therapies.
Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. The market structure is moderately fragmented with the presence of a large number of global and regional players. Moreover, the competitive environment in this market is intensifying due to the increasing number of research and development (R&D) innovations and mergers and acquisitions (M&A). The volume of new entrants is moderate in the digital therapeutics industry due to the fragmented market structure and low product differentiation and switching cost. In addition, the growing number of mhealth developers is contributing to the high threat of new entrants. However, the requirement of patents and high costs of advanced technologies along with stringent regulatory procedures, decreases the threat from new entrants.
What are Digital Therapeutics?
Digital therapeutics (DTx) is an evidence-based therapeutic intervention driven by high-quality software programs to prevent, manage, or treat a medical disorder or disease. It is a form of a software-as-a-medical device (SaMD) that relies on software interventions to bring about behavioral changes in patients and help treat their conditions. DTx is a fast-emerging class of therapies that utilizes software to treat disease as a standalone or for treatment optimization. It assists in preventing and managing a wide variety of diseases and conditions, such as type 2 diabetes, congestive heart failure, obesity, Alzheimer's disease, dementia, asthma, substance abuse, attention deficit hyperactivity disorder (ADHD), hypertension, anxiety, depression, and several others. DTx also aids in improving patient medication adherence and supporting healthcare professionals (HCPs) to manage their patients and businesses digitally.
The arrival of the COVID-19 pandemic can be described as a watershed moment for the healthcare industry. It changed the manner of healthcare delivery dramatically while exposing the lack of preparedness on the part of governments worldwide to adequately tackle a global healthcare emergency. Frontline health workers were involved in managing COVID-19 patients, but patients with other health conditions, especially chronic health conditions, experienced difficulties as their in-clinic visits were postponed or avoided. Moreover, as the outcomes of COVID-19 among patients with comorbidities, especially obesity, heart complications, and diabetes, were worse than those without, these patients were asked to be additionally vigilant. The pandemic also brought a fair share of mental health disorders, including depression, anxiety, and withdrawals, and their management was a challenge due to the lack of face-to-face visits. These interconnected events have made healthcare providers look out for digital health solutions to tackle health crisis. There was a positive trend observed during the COVID-19 outbreak in relation to the adoption of digital health technologies, which increased the efficiency and effectiveness of healthcare operations and service delivery. After the pandemic started, the adoption of DTx applications in various fields accelerated many folds. Additionally, the COVID-19 pandemic increased the adoption of virtual and home care technologies by transforming patient engagement and integrating data across the healthcare landscape.
At present, there is a rise in the demand for DTx among type 2 diabetes patients to manage the disease and enable them to use the internet of things (IoT)-enabled insulin pumps and other health monitoring systems. This, along with the increasing demand for digital behavior-monitoring treatment to ensure medication adherence and healthy lifestyle changes, represents one of the key factors supporting the growth of the market. In addition, the growing utilization of DTx to reduce the need for more follow-up checkups and relapses compared to traditional treatments is offering a favorable market outlook. Moreover, there is an increase in the prevalence of chronic diseases, such as heart disease, stroke, cancer, obesity, and arthritis. This, coupled with the rising awareness among the masses about personal health and fitness, is propelling the growth of the market. Additionally, the escalating demand for DTx to help doctors manage patient adherence to medical regimens and build an integrated health ecosystem that can enable the seamless transfer of data between different stakeholders, such as payers, providers, and pharmacies, is bolstering the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global digital therapeutics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on application and end use.
Diabetes
Obesity
CVD
CNS Disease
Respiratory Diseases
Smoking Cessation
Others
The report has provided a detailed breakup and analysis of the digital therapeutics market based on the application. This includes diabetes, obesity, CVD, CNS disease, respiratory diseases, smoking cessation, and others. According to the report, diabetes represented the largest segment due to the rising prevalence of diabetes, along with the high risk of associated conditions, such as cardiac arrests, kidney failure, and blindness, in diabetic patients. Moreover, the growing integration of DTx with numerous medical devices, such as insulin pumps, glucose blood meters, and wearable gadgets, is positively influencing the market.
Patients
Providers
Payers
Employers
Others
A detailed breakup and analysis of the digital therapeutics market based on the end use has also been provided in the report. This includes patients, providers, payers, employers, and others. According to the report, patients accounted for the largest market share due to the rising adoption of DTx among patients for numerous associated benefits pertaining to elective health management at an affordable cost. In addition, the increasing consumer inclination towards patient management systems for improving retention and compliance with post hospitalization follow-up visits is catalyzing the demand for DTx.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for digital therapeutics. Some of the factors driving the North America digital therapeutics market included the growing geriatric population, continuous upgradations in drug approval processes by the Food and Drug Administration (FDA), rising awareness about the benefits of DTx, etc. In addition, the growing utilization of DTx as a standalone therapy or in conjunction with medications, devices, and other therapies to optimize patient care and healthcare outcomes is offering a favorable market outlook.
2Morrow Inc.
Canary Health Inc.
Click Therapeutics Inc.
Mango Health Inc. (TrialCard Incorporated)
Noom Health Inc.
Omada Health Inc.
Pear Therapeutics, Inc.
Propeller Health (ResMed)
Teladoc Health Inc.
Voluntis Inc.
WellDoc Inc.
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.